We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+35.89%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.8B
AUM Growth
+$7.91M
Cap. Flow
-$287M
Cap. Flow %
-15.97%
Top 10 Hldgs %
51.42%
Holding
93
New
31
Increased
19
Reduced
14
Closed
21

Top Buys

Rank Stock Value
1
NVO
Novo Nordisk
NVO
+$72.8M
2
INCY icon
Incyte
INCY
+$61.9M
3
IDXX icon
Idexx Laboratories
IDXX
+$41.1M
4
ARGX icon
argenx
ARGX
+$40.5M
5
PODD icon
Insulet
PODD
+$37.5M

Top Sells

Rank Stock Value
1
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$437M
2
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$150M
3
IMGN
Immunogen Inc
IMGN
+$45.9M
4
LLY icon
Eli Lilly
LLY
+$37.6M
5
CYTK icon
Cytokinetics
CYTK
+$34.6M

Sector Composition

Rank Sector Weight
1 Healthcare 93.6%
2 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTRA icon
1
Natera
NTRA
$37.5B
$142M 7.9%
1,550,280
– –
VERA icon
2
Vera Therapeutics
VERA
$2.54B
$120M 6.71%
2,793,987
-673,169
-19% -$24M
ASND icon
3
Ascendis Pharma A/S
ASND
$16.7B
$114M 6.35%
754,032
– –
JBIO
4
Jade Biosciences
JBIO
$1.22B
$111M 6.19%
107,391
– –
MRK icon
5
Merck
MRK
$324B
$85.9M 4.79%
651,299
-206,672
-24% -$25.5M
XBI icon
6
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.1B
$80.7M 4.49%
+850,000
New +$78.9M
NVO
7
Novo Nordisk
NVO
$216B
$78.6M 4.38%
+611,884
New +$72.8M
INCY icon
8
Incyte
INCY
$23.5B
$75.6M 4.21%
1,327,178
+1,030,609
+348% +$61.9M
ARGX icon
9
argenx
ARGX
$57.4B
$58.8M 3.27%
149,300
+104,579
+234% +$40.5M
ISRG icon
10
Intuitive Surgical
ISRG
$121B
$56.2M 3.13%
140,880
+13,921
+11% +$5.26M
DYN icon
11
Dyne Therapeutics
DYN
$4.04B
$55M 3.06%
1,936,650
+923,145
+91% +$20.9M
INBX
12
DELISTED
Inhibrx, Inc. Common Stock
INBX
$45.5M 2.54%
1,302,645
+529,688
+69% +$19.3M
ELAN icon
13
Elanco Animal Health
ELAN
$12.4B
$41.6M 2.32%
2,555,547
+1,361,662
+114% +$21.3M
IDXX icon
14
Idexx Laboratories
IDXX
$42.9B
$40.6M 2.26%
+75,224
New +$41.1M
AZN icon
15
AstraZeneca
AZN
$263B
$40.4M 2.25%
298,357
-126,932
-30% -$16.8M
SNDX icon
16
Syndax Pharmaceuticals
SNDX
$1.84B
$38.3M 2.13%
1,608,540
+532,754
+50% +$11.9M
PODD icon
17
Insulet
PODD
$11.3B
$37.7M 2.1%
220,203
+201,203
+1,059% +$37.5M
YMAB
18
DELISTED
Y-mAbs Therapeutics
YMAB
$35.7M 1.99%
2,194,278
– –
IDYA icon
19
IDEAYA Biosciences
IDYA
$3.41B
$34.3M 1.91%
781,596
-677,285
-46% -$29.1M
CLDX icon
20
Celldex Therapeutics
CLDX
$2.77B
$33.7M 1.87%
801,777
-42,231
-5% -$1.73M
INZY
21
DELISTED
Inozyme Pharma
INZY
$32.8M 1.83%
4,280,308
– –
ALGN icon
22
Align Technology
ALGN
$12B
$31.3M 1.74%
+95,478
New +$28M
AVBP icon
23
ArriVent BioPharma
AVBP
$1.48B
$30.3M 1.69%
+1,696,752
New +$34.2M
TGTX icon
24
TG Therapeutics
TGTX
$8.58B
$30.2M 1.68%
+1,984,962
New +$31.6M
SRPT icon
25
Sarepta Therapeutics
SRPT
$1.66B
$29.5M 1.64%
+227,488
New +$27.9M
1
2 3 4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q1 2024 Portfolio in Review

As of Q1 2024, Sofinnova Investments held 93 positions worth $1.8B, up 0.44% from $1.79B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Sofinnova Investments withdrew a net $287M in Q1 2024, closing 21 positions and reducing 14 holdings. Its most notable exit was Karuna Therapeutics, Inc. Common Stock, an estimated $437M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 97% a quarter earlier, followed by Consumer Staples.

Against the trend, Sofinnova Investments opened a new position in Novo Nordisk worth $78.6M.

  • Sofinnova Investments's largest Q1 2024 buy was Novo Nordisk: 611,884 shares worth $78.6M.
  • Sofinnova Investments added most to Incyte in Q1 2024, an estimated $61.9M increase.
  • Sofinnova Investments's biggest Q1 2024 reduction was IDEAYA Biosciences, cutting an estimated $29.1M.
  • Sofinnova Investments fully exited Karuna Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $437M.
  • Sofinnova Investments's ten largest holdings make up 51% of its $1.8B portfolio in Q1 2024.
  • Sofinnova Investments opened 31 new positions and closed 21 in Q1 2024.
  • Sofinnova Investments's portfolio value rose 0.44% quarter-over-quarter to $1.8B.

Based on Sofinnova Investments's 13F filing for Q1 2024, filed 15 May 2024.